What do the developing brain and the Alzheimer’s brain have in common? Beth Stevens, Ph.D., a developmental neurologist, is investigating an important connection: the loss of synapses, where neurons connect with one another to transmit important signals.
Friday, Sep. 16, 2016
Find out about the exciting progress being made with gamma secretase modulators, a potential drug therapy for Alzheimer’s, in this one-hour webinar. Steven Wagner, Ph.D., principal investigator at UC San Diego's Department of Neuroscience, talks to David Shenk, senior adviser, Cure Alzheimer's Fund, about how the modulators work and what’s being done to get them to human trials. This webinar was recorded at our annual Research Consortium meeting in San Diego.
Dr. Rudy Tanzi talks to MD Magazine about recent developments in Alzheimer's research and the role that amyloid screening may play going forward. He also discusses best strategies for treatment.
Segment on Alzheimer's disease begins at 3:10.
Last week, many news stories broke about a recent study suggesting levels of amyloid, the sticky substance that builds up in the brain of Alzheimer's patients, may be lowered by the antidepressant Celexa. Dr. Rudy Tanzi, of Harvard Medical School/Massachusetts General Hospital and chair of Cure Alzheimer's Fund's Research Consortium, appeared on the CBS Morning Show to discuss the story.
Rudy Tanzi, Ph.D., appears on the CBS Morning Show to discuss a recent study about Alzheimer's and antidepressants.
The segment on Alzheimer's begins at 3:10.
An introduction to the problem of Alzheimer's and Cure Alzheimer's Fund's approach to solving it.
This video was originally shown at our 2013 Fall Symposium.
Five new publications by Gal Bitan, Ph.D., and colleagues of the David Geffen School of Medicine at UCLA have been released on developing the "molecular tweezer"* CLR01 as a therapeutic drug for Alzheimer's disease and other amyloidoses (conditions involving the build-up of insoluble amyloid proteins).
We collected your questions about Alzheimer's from our fall symposium and social media and presented them to Dr. Rudy Tanzi, chairman of our Research Consortium. Watch the videos below!
Dr. Rudy Tanzi of Harvard Medical School/Mass General Hospital talks to David Shenk about his research into CD33 inhibitors, which show promise in curtailing the damaging brain inflammation that occurs in Alzheimer's disease.
Dr. David Holtzman of Washington University in St. Louis explains his work on the tau protein in relation to Alzheimer's disease.
© 2005-2017 Cure Alzheimer's Fund. All rights reserved.